BRAF and non-small cell lung carcinoma: In vitro experiments have confirmed that the BRAF V600E mutation mediates resistance of NSCLC cells to osimertinib, and co-administration of the BRAF inhibitor encorafenib can restore sensitivity of resistant cells to osimertinib (155).